Chang Jonathan I, Huang Brian Z, Wu Bechien U
Pancreas. 2018 Feb;47(2):221-226. doi: 10.1097/MPA.0000000000000981.
The objective of this study was to evaluate whether disparities in pancreatic cancer diagnosis, treatment, and survival are reduced in an integrated health system.
We conducted a retrospective study (2006-2014) among patients with pancreatic cancer from Kaiser Permanente Southern California. Racial ethnic groups included non-Hispanic whites (NHW), non-Hispanic blacks (NHB), Hispanics, and Asians. We used multivariable and Cox regression analyses to evaluate disparities in diagnosis and treatment utilization (oncology care, surgery, time to surgery, chemotherapy) and overall survival, respectively.
Among 2103 patients, 54% were diagnosed with stage IV disease, 80% received oncology consultation, 20% received surgery with mean time to surgery 27 days (standard deviation, 36.8), 50.4% received chemotherapy. Mean overall survival was 8.6 months (standard deviation, 11.5). There were no differences in odds of stage IV diagnosis, oncology consultation, surgery, or time to surgery by racial ethnic group. Asians were more likely to receive chemotherapy (odds ratio, 1.59; 95% confidence interval [CI], 1.09-2.32) compared to NHW. NHB (hazard ratio, 0.78; 95% CI, 0.67-0.91) and Asians (hazard ratio, 0.81; 95% CI, 0.66-1.00) had improved survival compared to NHW.
Minorities were not disadvantaged in pancreatic cancer care. Improved health care coordination may improve current disparities.
本研究的目的是评估在一个综合医疗系统中,胰腺癌诊断、治疗和生存方面的差异是否有所减少。
我们对南加州凯撒医疗集团的胰腺癌患者进行了一项回顾性研究(2006 - 2014年)。种族群体包括非西班牙裔白人(NHW)、非西班牙裔黑人(NHB)、西班牙裔和亚裔。我们分别使用多变量分析和Cox回归分析来评估诊断和治疗利用(肿瘤护理、手术、手术时间、化疗)以及总生存方面的差异。
在2103例患者中,54%被诊断为IV期疾病,80%接受了肿瘤会诊,20%接受了手术,平均手术时间为27天(标准差为36.8),50.4%接受了化疗。平均总生存时间为8.6个月(标准差为11.5)。种族群体在IV期诊断、肿瘤会诊、手术或手术时间的几率上没有差异。与非西班牙裔白人相比,亚裔更有可能接受化疗(优势比为1.59;95%置信区间[CI]为1.09 - 2.32)。与非西班牙裔白人相比,非西班牙裔黑人(风险比为0.78;95% CI为0.67 - 0.91)和亚裔(风险比为0.81;95% CI为0.66 - 1.00)的生存情况有所改善。
少数族裔在胰腺癌护理方面并未处于劣势。改善医疗协调可能会改善当前的差异。